Healthy Skepticism Library item: 1962

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Rosack J.
Drug industry responds to complaints about marketing
Psychiatric News 2002 Jul 5; 37:(13):1
http://pn.psychiatryonline.org/cgi/content/full/37/13/1

Abstract:

A set of ‘crystal clear’ voluntary guidelines promulgated by the Pharmaceutical Research and Manufacturers of America (PhRMA), aimed at eliminating questionable marketing activities, went into effect July 1. Interactions should be focused on informing health care professionals about products, providing scientific and educational information, and supporting medical research and education. APA President comments that these guidelines do not remove the necessity for psychiatrists and facilities to draw their own lines. There may be room for differing interpretations. The code allows payment and reimbursement to clearly defined “bona fide consultants” and participating company’s bureau speakers but not to non-consultant or non-faculty attendees at company-sponsored meetings. Scholarship and educational funding is permissible if the selection of the individuals is made by the academic or training institution. Reminder items of minimal value are permitted as are items “$100 or less” if they are primarily for the benefit of patients, and offered only occasionally. Other items are out of the question. Companies contacted by Psychiatric News indicated they already have internal policies at least as stringent, if not more so, than the PhRMA guidelines.

Keywords:
news story policy statement & guideline United States